Board strengthened with significant international medtech and financial expertise
Louvain-La-Neuve, Belgium, 25 August 2020 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the strengthening of its Board of Directors and Audit Committee with the appointment of Dr. Richard Hausmann and Christine Dubus as Non-Executive Directors.
Dr. Richard Hausmann has over 30 years’ experience in the medtech industry, having most recently served as President and CEO of Elekta (EKTA-B.ST) where he was responsible for the launch and global expansion of Unity, Elekta’s high-field magnetic resonance-guided radiation therapy solution. Prior to this, he led GE’s Magnetic Resonance division as President and CEO for four years, during which time the business saw a significant increase in its global market share. Dr. Hausmann also held several senior positions at Siemens over a 23 year career, most notably serving as President and CEO of Siemens Computed Tomography and working for several years in its Magnetic Resonance business. In addition he acted as CEO of Siemens China, responsible for the company’s entire portfolio in its core emerging market. Dr. Hausmann will be a member of both the Board of Directors and the Audit Committee.
Christine Dubus is a highly regarded finance leader with more than 30 years’ experience. She currently serves as Executive Director at CIC Conseil, Crédit Mutuel Alliance Fédérale's M&A subsidiary, where she supports the development of companies in France and internationally. Ms. Dubus is a chartered accountant and started her career as a financial auditor in 1989 at Mazars, the global audit, accounting and consulting group. In 1997 she was made Partner in Charge of Audit Activities, and has since supported numerous groups in their international development in the industrial and services sector. She currently serves on the Board of several other international companies including Columbus, Mobivia and Via ID and serves as an expert on the Audit Committee of Decathlon. Ms. Dubus will be a member of the Board of Directors and will chair the IBA Audit Committee.
Pierre Mottet, Chairman of IBA, commented: “We are delighted to welcome Richard and Christine to the Board bringing significant industry knowledge and financial expertise. Richard’s experience in bringing new technologies to the market and growing market share will be invaluable as we look to further capitalize on our market leading position in proton therapy. This, combined with Christine’s significant global financial experience, gives us further strong expertise to support IBA in its growth ambitions.”
Dr. Richard Hausmann said: “As a global leader in particle acceleration, IBA is a highly respected company in the medtech sector. I look forward to working with the rest of the Board to utilize my experience in the field and support the future growth of the business.”
Christine Dubus said: “IBA is a truly international business, with operations across the globe. It is a pleasure to join a highly innovative company that is transforming cancer care for patients.”
***
IBA also announces with great sadness the passing of Eric de Lamotte, last week. Eric was IBA’s CFO for several years, leading up to the IPO of the Company and was instrumental in this process. Eric was also a member of IBA’s Board of Directors and Audit Committee until earlier this year, when he resigned for health reasons. In addition to his passionate support for IBA, Eric was a philanthropist involved in several charitable initiatives, in particular in the Congo, where he had spent time as a young professional. A well-loved figure at IBA, he was known not only for his professionalism but also for his humorous personality and personal rapport with employees. His untimely death is mourned by all of us at IBA and we extend our deepest condolences to his family
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
For further information, please contact:
IBA
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com
Thomas Ralet
Head of Corporate Communication
+32 10 475 890
communication@iba-group.com
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Angela Gray
+44 (0) 20 3709 5700
IBA@consilium-comms.com